Aura Biosciences
AURA
32 hedge funds and large institutions have $220M invested in Aura Biosciences in 2021 Q4 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
44.78% more ownership
Funds ownership: 0% → 44.78% (+45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$73.5M |
| 2 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
+$54.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$41.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.4M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$18M |
Top Sellers
AURA Hedge Fund Activity: Q4 2021 in Review
32 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q4 2021, worth a combined $220M.
Buyers outnumbered sellers: 32 funds opened new AURA positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Matrix Capital Management Company, opening a new position worth an estimated $73.5M.
- 32 institutional investors held Aura Biosciences (AURA) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $220M of Aura Biosciences stock for Q4 2021.
- 32 funds opened new Aura Biosciences positions in Q4 2021 and 0 closed out, a net change of +32 holders.
- The largest Aura Biosciences buyer in Q4 2021 was Matrix Capital Management Company, an estimated $73.5M added.
Based on aggregated 13F filings for Q4 2021.